Windtree Therapeutics reduces preferred shares by conversion and redemption Jul 29, 2025 09:02AM
Windtree Therapeutics partners with Kraken for BNB custody services Jul 22, 2025 09:03AM
Windtree Therapeutics enters $60 million BNB crypto treasury deal Jul 16, 2025 09:23AM
Windtree Therapeutics, Inc. (WINT) Files for 62.6M Share Offering by Selling Stockholders Jul 10, 2025 09:26AM
Windtree Therapeutics, Inc. (WINT) Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure Jul 2, 2025 09:01AM


Jun 30, 2025 09:02AM Windtree Therapeutics, Inc. (WINT) reaches planned enrollment for Phase 2 SEISMiC study
Jun 16, 2025 08:02AM Windtree Therapeutics (WINT) Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
Jun 11, 2025 09:01AM Windtree Therapeutics, Inc. (WINT) Receives Offer for Its Preclinical Oncology Drug Candidate
Jun 10, 2025 08:01AM Windtree Therapeutics, Inc. (WINT) to Acquire Titan Environmental Services (TESI)
Jun 9, 2025 08:15AM Aditxt, Inc (ADTX) appoints Saundra Pelletier to Board
Jun 3, 2025 04:07PM Windtree Therapeutics (WINT) Announces Plan for Cryptocurrency Treasury Policy
May 6, 2025 08:19AM Windtree Therapeutics, Inc. (WINT) Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
Mar 24, 2025 08:01AM Windtree Therapeutics, Inc. (WINT) Regains Nasdaq Compliance
Mar 20, 2025 08:02AM Windtree Therapeutics, Inc. (WINT) Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Mar 4, 2025 08:03AM Windtree Therapeutics, Inc. (WINT) Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure
Feb 18, 2025 08:01AM Windtree Therapeutics, Inc. (WINT) Announces 1:50 Reverse Share Split
Feb 12, 2025 08:05AM Windtree Therapeutics (WINT) Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
Jan 13, 2025 08:01AM Windtree Therapeutics, Inc. (WINT) Appoints Leanne Kelly to its Board
Jan 8, 2025 08:01AM Windtree Therapeutics, Inc. (WINT) Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets
Nov 14, 2024 08:00AM Windtree Therapeutics, Inc. (WINT) Announces Leadership Transition Plan
Oct 23, 2024 08:05AM Windtree Therapeutics (WINT) Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
Oct 17, 2024 08:16AM Windtree (WINT) Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
Oct 9, 2024 08:01AM Windtree Therapeutics (WINT) Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
Sep 30, 2024 08:15AM Windtree Therapeutics (WINT) Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiog
Sep 25, 2024 08:15AM Windtree Therapeutics (WINT) Reports Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime
Aug 20, 2024 04:32PM Windtree Therapeutics, Inc. (WINT) Misses Q2 EPS by 2091c
Aug 14, 2024 04:05PM Windtree Therapeutics, Inc. (WINT) Appoints Saundra Pelletier and Jed Latkin to its Board
Jul 9, 2024 06:57AM Windtree Therapeutics (WINT) PT Raised to $7 at H.C. Wainwright